Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last C$0.48 CAD
Change Today -0.005 / -1.04%
Volume 10.6K
As of 11:08 AM 07/31/15 All times are local (Market data is delayed by at least 15 minutes).

acasti pharma inc (APO) Snapshot

Previous Close
Day High
Day Low
52 Week High
09/15/14 - C$1.20
52 Week Low
06/16/15 - C$0.35
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for ACASTI PHARMA INC (APO)

Related News

No related news articles were found.

acasti pharma inc (APO) Related Businessweek News

No Related Businessweek News Found

acasti pharma inc (APO) Details

Acasti Pharma Inc., a biopharmaceutical company, focuses on the research, development, and commercialization of therapies for the treatment and prevention of various cardiometabolic disorders primarily abnormalities in blood lipids. The company offers ONEMIA, a medical food for the dietary management of omega-3 phospholipids deficiency, and related abnormal lipid profiles and cardiometabolic disorders. It also develops CaPre, a prescription drug candidate for the prevention and treatment of cardiometabolic disorders, including hypertriglyceridemia. Acasti Pharma Inc. distributes ONEMIA through physicians, distributors, and pharmacies in the United States and internationally. The company was incorporated in 2002 and is headquartered in Laval, Canada. Acasti Pharma Inc. is a subsidiary of Neptune Technologies & Bioressources Inc.

7 Employees
Last Reported Date: 05/27/15
Founded in 2002

acasti pharma inc (APO) Top Compensated Officers

Chief Operating Officer
Total Annual Compensation: C$184.1K
Compensation as of Fiscal Year 2015.

acasti pharma inc (APO) Key Developments

Acasti Pharma Inc. Reports Unaudited Earnings Results for the First Quarter Ended May 31, 2015

Acasti Pharma Inc. reported unaudited earnings results for the first quarter ended May 31, 2015. For the quarter, the company reported revenue from sales of $5,154 against $56,073 a year ago. Loss from operating activities was $2,609,081 against $2,970,780 a year ago. Net loss and total comprehensive loss for the period was $965,746 or $0.01 per basic and diluted share against net earnings and total comprehensive income for the period of $1,356,421 or $0.01 per basic and diluted share a year ago. Net cash used in operating activities was $964,493 against $500,860 a year ago. Acquisition of equipment was $128,772. Adjusted LBITDA was $1,946,000 compared to $1,695,000 in the prior year. The year-over-year decrease in adjusted EBITDA was mainly due to the higher R&D expenses. The quarterly net loss over the prior year's net profit was mainly attributable to the decrease in finance income associated with the change in the fair value of Acasti's derivative warrant liability arising from its 2013 public offering.

Acasti Pharma Inc. to Adopt Amended and Restated By-Laws

Notice is hereby given that the annual and special meeting of the shareholders of Acasti Phama Inc. will be held on July 14, 2015, to consider and adoption of the amended and restated by-laws of the Corporation.

Acasti Pharma Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended February 28, 2015

Acasti Pharma Inc. reported earnings results for the fourth quarter and full year ended February 28, 2015. For the quarter, the company reported revenues were $178,000 against $201,000 for the quarter ended February 28, 2014. Adjusted EBITDA was negative $2,263,000 against negative $977,000 in the prior year. Net loss was $2,311,000 or $0.02 per share for the quarter, versus a net loss of $2,553,000 or $0.02 per share in the prior year. For the full year, the company reported revenues were $271,000 against $501,000 for the year ended February 28, 2014. Adjusted EBITDA was negative $8,506,000 against $5,584,000 in the prior year. A net loss of $1,655,000 or $0.02 per share was recorded for the year, versus a net loss of $11,612,000 or $0.14 per share in the prior year. Sales in both years were generated from the commercialization of Onemia®, the Corporation's medical food product. Acasti relies on a limited number of distributors and clients and therefore revenues may vary significantly from quarter to quarter. The year-over-year decline in adjusted EBITDA was largely due to higher R&D expenses.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
APO:CN C$0.48 CAD -0.005

APO Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Enzymotec Ltd $8.10 USD -0.41
View Industry Companies

Industry Analysis


Industry Average

Valuation APO Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 223.6x
Price/Book 1.5x
Price/Cash Flow NM Not Meaningful
TEV/Sales 145.6x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ACASTI PHARMA INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at